[go: up one dir, main page]

CL2018002548A1 - Regulación del metabolismo de ornitina para aumentar el contenido de glicoformas ricas en manosa de proteínas recombinantes.(divisional solicitud 201601786) - Google Patents

Regulación del metabolismo de ornitina para aumentar el contenido de glicoformas ricas en manosa de proteínas recombinantes.(divisional solicitud 201601786)

Info

Publication number
CL2018002548A1
CL2018002548A1 CL2018002548A CL2018002548A CL2018002548A1 CL 2018002548 A1 CL2018002548 A1 CL 2018002548A1 CL 2018002548 A CL2018002548 A CL 2018002548A CL 2018002548 A CL2018002548 A CL 2018002548A CL 2018002548 A1 CL2018002548 A1 CL 2018002548A1
Authority
CL
Chile
Prior art keywords
cell
inhibitor
ornitine
rich
content
Prior art date
Application number
CL2018002548A
Other languages
English (en)
Inventor
Sohye Kang
Chung-Jr Huang
Hedieh Barkhordarian
Pavel Bondarenko
Zhongqi Zhang
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52273554&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2018002548(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of CL2018002548A1 publication Critical patent/CL2018002548A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/005—Glycopeptides, glycoproteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/38—Chemical stimulation of growth or activity by addition of chemical compounds which are not essential growth factors; Stimulation of growth by removal of a chemical compound
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0681—Cells of the genital tract; Non-germinal cells from gonads
    • C12N5/0682—Cells of the female genital tract, e.g. endometrium; Non-germinal cells from ovaries, e.g. ovarian follicle cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/32—Amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/32—Amino acids
    • C12N2500/33—Amino acids other than alpha-amino carboxylic acids, e.g. beta-amino acids, taurine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/46—Amines, e.g. putrescine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/90—Serum-free medium, which may still contain naturally-sourced components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/99—Serum-free medium
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/70—Enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/70—Enzymes
    • C12N2501/72—Transferases [EC 2.]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/70—Enzymes
    • C12N2501/73—Hydrolases (EC 3.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/999—Small molecules not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2521/00—Culture process characterised by the use of hydrostatic pressure, flow or shear forces

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Reproductive Health (AREA)
  • Cell Biology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

LA INVENCIÓN DIVULGA UN MÉTODO PARA AUMENTAR EL CONTENIDO DE GLICOFORMAS RICAS EN MANOSA DE UNA PROTEÍNA RECOMBINANTE QUE COMPRENDE CULTIVAR UNA CÉLULA HOSPEDERA QUE EXPRESA LA PROTEÍNA RECOMBINANTE EN UN CULTIVO CELULAR QUE COMPRENDE UN COMPUESTO SELECCIONADO DEL GRUPO ORNITINA, ARGININA, UN INHIBIDOR DE ORNITINA AMINOTRANSFERASA, UN INHIBIDOR DE ÓXIDO NÍTRICO SINTASA, Y UN INHIBIDOR DE ARQININA DESCARBOXILASA, DONDE LA PRODUCCIÓN DE ORNITINA EN LA CÉLULA HOSPEDERA DISMINUYE AL AUMENTAR LA ACUMULACIÓN DE ORNITINA CUANDO ES COMPARARLO CON LA CÉLULA HOSPEDERA QUE EXPRESA LA PROTEÍNA RECOMBINANTE CULTIVADA EN UN CULTIVO CELULAR QUE CARECE DE UNO DE LOS COMPUESTOS SELECCIONADOS DEL GRUPO QUE CONSISTE EN ORNITINA, ARGININA, UN INHIBIDOR DE ORNITINA AMINOTRANSFERASA, UN INHIBIDOR DE ÓXIDO NÍTRICO SINTASA Y UN INHIBIDOR DE LA ARGININA DECARBOXILASA. Y LA PROTEÍNA RECOMBINANTE TIENE UN AUMENTO EN EL CONTENIDO DE GLICOFORMAS RICAS EN MANOSA QUE LA PROTEÍNA RECOMBINANTE EXPRESADA EN EL CULTIVO CELULAR QUE CARECE DE UNO DE LOS COMPUESTOS SELECCIONADOS DEL GRUPO QUE CONSISTE EN ORNÍTINA, ARGININA, UN INHIBIDOR DE ORNITINA AMINOTRANSFERASA, UN INHIBIDOR DE ÓXIDO NÍTRICO SINTASA Y UN INHIBIDOR DE LA ARGININA DECARBOXÍLASA.
CL2018002548A 2014-01-13 2018-09-06 Regulación del metabolismo de ornitina para aumentar el contenido de glicoformas ricas en manosa de proteínas recombinantes.(divisional solicitud 201601786) CL2018002548A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201461926481P 2014-01-13 2014-01-13

Publications (1)

Publication Number Publication Date
CL2018002548A1 true CL2018002548A1 (es) 2018-10-26

Family

ID=52273554

Family Applications (3)

Application Number Title Priority Date Filing Date
CL2016001786A CL2016001786A1 (es) 2014-01-13 2016-07-12 Regulación del metabolismo de ornitina para manipular el contenido de glicoformas ricas en manosa de proteínas recombinantes.
CL2018002548A CL2018002548A1 (es) 2014-01-13 2018-09-06 Regulación del metabolismo de ornitina para aumentar el contenido de glicoformas ricas en manosa de proteínas recombinantes.(divisional solicitud 201601786)
CL2022000470A CL2022000470A1 (es) 2014-01-13 2022-02-25 Método para disminuir el contenido de glicoformas ricas en manosa de una proteína recombinante (divisional de la solicitud de patente no. 201601786)

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CL2016001786A CL2016001786A1 (es) 2014-01-13 2016-07-12 Regulación del metabolismo de ornitina para manipular el contenido de glicoformas ricas en manosa de proteínas recombinantes.

Family Applications After (1)

Application Number Title Priority Date Filing Date
CL2022000470A CL2022000470A1 (es) 2014-01-13 2022-02-25 Método para disminuir el contenido de glicoformas ricas en manosa de una proteína recombinante (divisional de la solicitud de patente no. 201601786)

Country Status (14)

Country Link
US (2) US10513723B2 (es)
EP (1) EP3094735A1 (es)
JP (1) JP6732660B2 (es)
KR (1) KR102381791B1 (es)
CN (2) CN112481337B (es)
AU (3) AU2014376225C1 (es)
BR (2) BR122020004385B1 (es)
CA (1) CA2936104C (es)
CL (3) CL2016001786A1 (es)
EA (2) EA039141B1 (es)
IL (1) IL246727B (es)
MX (2) MX376230B (es)
SG (2) SG10201806643WA (es)
WO (1) WO2015105609A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR095196A1 (es) 2013-03-15 2015-09-30 Regeneron Pharma Medio de cultivo celular libre de suero
TWI797060B (zh) 2015-08-04 2023-04-01 美商再生元醫藥公司 補充牛磺酸之細胞培養基及用法
AU2018298039B2 (en) * 2017-07-06 2023-02-02 Regeneron Pharmaceuticals, Inc. Cell culture process for making a glycoprotein
RU2672318C1 (ru) * 2017-09-19 2018-11-13 Общество с ограниченной ответственностью "Международный Биотехнологический Центр "Генериум" Способ получения моноклональных антител терапевтического назначения с помощью непрерывного культивирования клеток сно
CN111527214B (zh) 2017-12-20 2024-08-06 阿雷斯贸易股份有限公司 用聚醚离子载体调整蛋白质甘露糖基化状况的方法
US12297451B1 (en) 2019-10-25 2025-05-13 Regeneron Pharmaceuticals, Inc. Cell culture medium
CN111671051B (zh) * 2020-07-30 2022-01-11 广州同康生物科技有限公司 一种整粒黄豆中嘌呤的脱除工艺

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6936694B1 (en) 1982-05-06 2005-08-30 Intermune, Inc. Manufacture and expression of large structural genes
AU588819B2 (en) 1984-10-29 1989-09-28 Immunex Corporation Cloning of human granulocyte-macrophage colony stimulating factor gene
US4968607A (en) 1987-11-25 1990-11-06 Immunex Corporation Interleukin-1 receptors
US5075222A (en) 1988-05-27 1991-12-24 Synergen, Inc. Interleukin-1 inhibitors
AU643427B2 (en) 1988-10-31 1993-11-18 Immunex Corporation Interleukin-4 receptors
US5395760A (en) 1989-09-05 1995-03-07 Immunex Corporation DNA encoding tumor necrosis factor-α and -β receptors
ATE236249T1 (de) 1989-09-12 2003-04-15 Hoffmann La Roche Tfn-bindende proteine
US6204363B1 (en) 1989-10-16 2001-03-20 Amgen Inc. Stem cell factor
US5272064A (en) 1989-12-19 1993-12-21 Amgen Inc. DNA molecules encoding platelet-derived growth factor B chain analogs and method for expression thereof
US5149792A (en) 1989-12-19 1992-09-22 Amgen Inc. Platelet-derived growth factor B chain analogs
US5350683A (en) 1990-06-05 1994-09-27 Immunex Corporation DNA encoding type II interleukin-1 receptors
WO1991018982A1 (en) 1990-06-05 1991-12-12 Immunex Corporation Type ii interleukin-1 receptors
DE69332981T2 (de) 1992-10-23 2004-05-19 Immunex Corp., Seattle Methoden zur herstellung löslicher, oligomerer proteine
US5554512A (en) 1993-05-24 1996-09-10 Immunex Corporation Ligands for flt3 receptors
US5981713A (en) 1994-10-13 1999-11-09 Applied Research Systems Ars Holding N.V. Antibodies to intereleukin-1 antagonists
US5721121A (en) 1995-06-06 1998-02-24 Genentech, Inc. Mammalian cell culture process for producing a tumor necrosis factor receptor immunoglobulin chimeric protein
JP4435304B2 (ja) 1995-06-29 2010-03-17 イミュネックス・コーポレーション アポトーシスを誘導するサイトカイン
US6613544B1 (en) 1995-12-22 2003-09-02 Amgen Inc. Osteoprotegerin
US6096728A (en) 1996-02-09 2000-08-01 Amgen Inc. Composition and method for treating inflammatory diseases
US6271349B1 (en) 1996-12-23 2001-08-07 Immunex Corporation Receptor activator of NF-κB
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
US6337072B1 (en) 1998-04-03 2002-01-08 Hyseq, Inc. Interleukin-1 receptor antagonist and recombinant production thereof
AU1920301A (en) 1999-11-17 2001-05-30 Immunex Corporation Receptor activator of nf-kappa b
US6544424B1 (en) 1999-12-03 2003-04-08 Refined Technology Company Fluid filtration system
AU2001263466C1 (en) 2000-05-26 2006-10-26 Bristol-Myers Squibb Company Soluble CTLA4 mutant molecules and uses thereof
US20030104996A1 (en) * 2001-08-30 2003-06-05 Tiansheng Li L-methionine as a stabilizer for NESP/EPO in HSA-free formulations
US8053238B2 (en) 2005-10-31 2011-11-08 Unhwa Corporation Isolated population of plant single cells and method of preparing the same
US20070190057A1 (en) * 2006-01-23 2007-08-16 Jian Wu Methods for modulating mannose content of recombinant proteins
WO2008154014A2 (en) * 2007-06-11 2008-12-18 Amgen Inc. A method for culturing mammalian cells to improve recombinant protein production
US9133493B2 (en) 2011-04-21 2015-09-15 Amgen Inc. Method for culturing mammalian cells to improve recombinant protein production
KR102358951B1 (ko) 2011-07-01 2022-02-08 암젠 인크 포유동물 세포 배양

Also Published As

Publication number Publication date
SG11201605640UA (en) 2016-08-30
MX2016009084A (es) 2016-10-13
KR102381791B1 (ko) 2022-03-31
US11254963B2 (en) 2022-02-22
AU2018226416C1 (en) 2025-11-06
MX384153B (es) 2025-03-14
CA2936104C (en) 2022-04-19
AU2014376225A1 (en) 2016-07-21
CN106029896A (zh) 2016-10-12
CL2022000470A1 (es) 2022-10-21
EA201691426A1 (ru) 2016-11-30
JP6732660B2 (ja) 2020-07-29
BR112016015797A2 (es) 2017-10-03
AU2018226416B2 (en) 2020-08-27
EA039141B1 (ru) 2021-12-09
EA202191909A1 (ru) 2022-01-31
AU2018226416A1 (en) 2018-09-27
AU2020260443A1 (en) 2020-11-26
WO2015105609A1 (en) 2015-07-16
BR122020004385B1 (pt) 2022-10-04
US20160333385A1 (en) 2016-11-17
US20200071738A1 (en) 2020-03-05
CA2936104A1 (en) 2015-07-16
MX376230B (es) 2025-03-07
EP3094735A1 (en) 2016-11-23
CN106029896B (zh) 2020-10-27
JP2017501749A (ja) 2017-01-19
CN112481337B (zh) 2024-06-25
AU2014376225C1 (en) 2025-06-05
IL246727A0 (en) 2016-08-31
CN112481337A (zh) 2021-03-12
AU2020260443B2 (en) 2022-10-27
US10513723B2 (en) 2019-12-24
SG10201806643WA (en) 2018-09-27
KR20160104073A (ko) 2016-09-02
BR112016015797B1 (pt) 2022-10-11
IL246727B (en) 2020-05-31
CL2016001786A1 (es) 2017-06-02
AU2014376225B2 (en) 2018-06-07

Similar Documents

Publication Publication Date Title
CL2018002548A1 (es) Regulación del metabolismo de ornitina para aumentar el contenido de glicoformas ricas en manosa de proteínas recombinantes.(divisional solicitud 201601786)
MX2018005829A (es) Composiciones para tratar el cabello.
MX2018007932A (es) Composiciones de inoculante estables y metodos para producir las mismas.
MX2021015789A (es) Reduccion de la viscosidad de formulaciones farmaceuticas.
MX2017008817A (es) Composiciones y metodos para la glicosilacion de proteinas.
CR20180525A (es) Producción de ácido ribonucleico libre de células
MX2017015236A (es) Beneficios de la suplementacion con n-acetilcisteina y glicina para mejorar los niveles de glutation.
EA201890949A1 (ru) СЛОЖНОЭФИРНЫЕ ИНГИБИТОРЫ АЦЕТИЛ-КоА-КАРБОКСИЛАЗЫ И ВАРИАНТЫ ИХ ПРИМЕНЕНИЯ
AR096869A1 (es) Neurotoxinas catiónicas
SG10201803042PA (en) Anti-tim-3 antibodies
DK3491100T3 (da) Lysin: hydrochlorid syntetiske syrekompositioner som alternativer til konventionelle syrer i olie- og gasindustrien
NI201600043A (es) Ácidos grasos octanoico, nonanoico y decanoico con un adulticida piretroide
ES2721309T3 (es) Composición para preparar tagatosa y método para preparar tagatosa a partir de fructosa
CR20170425A (es) Nuevas proteínas específicas para pioverdina y pioquelina
EA202090632A1 (ru) Способы и композиции для лечения расстройств с использованием фоллистатиновых полипептидов
BR112018010381A2 (pt) composições para tratamento de cabelo, condicionadora de cabelo e para alteração da cor do cabelo, sistema para tratamento de cabelo, métodos para tratamento de cabelo e para alteração da cor do cabelo, e, kit de multicompartimentos.
BR112016024494A2 (pt) análogos de peptídeo com sonda(s) de aminoácidos ramificados
CU24405B1 (es) Proteínas de variantes de secuencias de aminoácidos de cry1da1 activas para lepidópteros
CL2017002427A1 (es) Producción de ácido ribonucleico libre de células.
AR099500A1 (es) Composición para el desmucilaginado enzimático de aceite
CR20170020A (es) Variantes de proteínas de unión al factor h y métodos de uso de estas
BR112018003714A2 (pt) composições de ácido de peso aumentado que compreendem aminoácidos
MX382116B (es) Composiciones que comprenden acido 15-hidroxieicosapentaenoico (15-hepe) y metodos para tratar o prevenir la fibrosis usando las mismas.
BR112016028561A8 (pt) composição e forma de dosagem compreendendo um óleo marinho que compreende ácidos graxos, e, uso das mesmas
MX2019013251A (es) Una composicion nutricional para usarse para mejorar la atencion y/o reducir la impulsividad.